Skip to main content
. 2019 Feb 13;54(4):1282–1294. doi: 10.3892/ijo.2019.4715

Figure 3.

Figure 3

LEF-1 is directly targeted by miR-300 in hepatocellular carcinoma. (A) Bioinformatics analysis of miR-300 was performed to predict the binding sites in 3′UTR of the LEF-1 coding sequence. (B) Fluorescent reporter assay was conducted at 48 h after transfection with miR-300 mimic (miR-300) or miR-300 inhibitor in Huh7 and Hep3B cells. (n=3; **P<0.01). (C) The protein levels of LEF-1 were detected at 48 h after transfection with miR-300 mimic (miR-300) or miR-300 inhibitor in Huh-7 and Hep3B. (D) The mRNA levels of LEF-1 at 48 h after transfection with miR-300 mimic (miR-300) or miR-300 inhibitor in Huh-7 and Hep3B. (n=3; *P<0.05, **P<0.01 vs. control). LEF-1, lymphoid enhancer-binding factor 1; 3′UTR, 3′untranslated region; miR, microRNA; WT, wild-type; Mut, mutant.